COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial.
作者信息
Mancia Giuseppe
机构信息
University of Milano-Bicocca, Milan, Italy.
出版信息
Cardiovasc Res. 2020 Dec 1;116(14):e198-e199. doi: 10.1093/cvr/cvaa325.
Abstract
摘要
相似文献
1
COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial.2019冠状病毒病、高血压与肾素-血管紧张素-醛固酮系统阻滞剂：BRACE-CORONA试验
Cardiovasc Res. 2020 Dec 1;116(14):e198-e199. doi: 10.1093/cvr/cvaa325.
2
Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.血管紧张素转换酶 2 和肾素血管紧张素系统抑制剂在 COVID-19 中的应用：最新进展。
High Blood Press Cardiovasc Prev. 2021 Mar;28(2):129-139. doi: 10.1007/s40292-021-00439-9. Epub 2021 Feb 26.
3
COVID-19, hypertension, and renin-angiotensin-aldosterone system inhibitors: Much ado about nothing or real problem to be solved?新型冠状病毒肺炎、高血压与肾素-血管紧张素-醛固酮系统抑制剂：小题大做还是亟待解决的实际问题？
J Clin Hypertens (Greenwich). 2020 Nov;22(11):1984-1986. doi: 10.1111/jch.14045. Epub 2020 Sep 20.
4
RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.血管紧张素受体拮抗剂（RAAS 抑制剂）与 COVID-19 患者的死亡率无关：来自意大利一项观察性多中心研究和对 19 项研究的荟萃分析的结果。
Vascul Pharmacol. 2020 Dec;135:106805. doi: 10.1016/j.vph.2020.106805. Epub 2020 Sep 28.
5
Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension.血管紧张素转化酶抑制剂/血管紧张素Ⅱ受体拮抗剂对高血压患者严重急性呼吸综合征冠状病毒 2 感染风险和结局的影响。
Korean J Intern Med. 2021 Mar;36(Suppl 1):S123-S131. doi: 10.3904/kjim.2020.390. Epub 2021 Feb 10.
6
Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.肾素-血管紧张素系统抑制剂的使用对重症新冠肺炎合并高血压患者死亡率的影响：一项回顾性观察研究
J Int Med Res. 2020 Dec;48(12):300060520979151. doi: 10.1177/0300060520979151.
7
Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension.血压控制及肾素-血管紧张素-醛固酮系统抑制剂的应用对合并高血压的 COVID-19 患者结局的影响。
J Clin Hypertens (Greenwich). 2020 Nov;22(11):1974-1983. doi: 10.1111/jch.14038. Epub 2020 Oct 2.
8
Angiotensin Receptor Blockers Are Not Just for Hypertension Anymore.血管紧张素受体阻滞剂的作用已不仅限于降血压。
Physiology (Bethesda). 2021 May 1;36(3):160-173. doi: 10.1152/physiol.00036.2020.
9
The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients.在新冠肺炎患者中使用血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂的争议。
J Renin Angiotensin Aldosterone Syst. 2021 Jan-Dec;22(1):1470320320987118. doi: 10.1177/1470320320987118.
10
Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019.血管紧张素转换酶 2 与 2019 冠状病毒病时代的肾脏疾病。
Korean J Intern Med. 2021 Mar;36(2):247-262. doi: 10.3904/kjim.2020.355. Epub 2020 Oct 16.
引用本文的文献
1
Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial.根据疾病严重程度，在 COVID-19 住院患者中停止与继续使用 ACEIs 和 ARBs：BRACE CORONA 试验的见解。
Am Heart J. 2022 Jul;249:86-97. doi: 10.1016/j.ahj.2022.04.001. Epub 2022 Apr 8.
2
Hypertension and its management in COVID-19 patients: The assorted view.新型冠状病毒肺炎患者的高血压及其管理：不同观点
Int J Cardiol Cardiovasc Risk Prev. 2021 Dec;11:200121. doi: 10.1016/j.ijcrp.2021.200121. Epub 2021 Nov 13.
3
Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure.肾素-血管紧张素系统阻滞剂与肾衰竭患者 COVID-19 相关死亡率的关系。
Clin J Am Soc Nephrol. 2021 Jul;16(7):1061-1072. doi: 10.2215/CJN.18961220. Epub 2021 Jun 4.
4
Hypertension, a Moving Target in COVID-19: Current Views and Perspectives.高血压，COVID-19 中的一个动态目标：当前观点和视角。
Circ Res. 2021 Apr 2;128(7):1062-1079. doi: 10.1161/CIRCRESAHA.121.318054. Epub 2021 Apr 1.
5
An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19.一项评估氯沙坦治疗COVID-19中恶化呼吸疾病安全性的开放标签试验。
Front Med (Lausanne). 2021 Feb 17;8:630209. doi: 10.3389/fmed.2021.630209. eCollection 2021.
6
Chest Imaging of Patients with Sarcoidosis and SARS-CoV-2 Infection. Current Evidence and Clinical Perspectives.结节病与SARS-CoV-2感染患者的胸部影像学。当前证据与临床观点。
Diagnostics (Basel). 2021 Jan 27;11(2):183. doi: 10.3390/diagnostics11020183.
7
Renin-angiotensin-aldosterone inhibitors and COVID-19: nearing the end of a media-fuelled controversy.肾素-血管紧张素-醛固酮抑制剂与新型冠状病毒肺炎：媒体引发的争议即将结束。
Eur J Heart Fail. 2021 Mar;23(3):486-488. doi: 10.1002/ejhf.2098. Epub 2021 Jan 25.
本文引用的文献
1
Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality.2019冠状病毒病中继续使用与停用血管紧张素转换酶抑制剂或血管紧张素II受体阻滞剂：对血压控制和死亡率的影响
Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):412-414. doi: 10.1093/ehjcvp/pvaa056.
2
Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study.高血压和降压治疗与 COVID-19 死亡率的关联：一项回顾性观察研究。
Eur Heart J. 2020 Jun 7;41(22):2058-2066. doi: 10.1093/eurheartj/ehaa433.
3
Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂与 COVID-19 住院风险的相关性：一项基于病例的队列研究
Lancet. 2020 May 30;395(10238):1705-1714. doi: 10.1016/S0140-6736(20)31030-8. Epub 2020 May 14.
4
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2441-2448. doi: 10.1056/NEJMoa2008975. Epub 2020 May 1.
5
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.肾素-血管紧张素-醛固酮系统阻滞剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2431-2440. doi: 10.1056/NEJMoa2006923. Epub 2020 May 1.
6
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.住院 COVID-19 合并高血压患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的住院使用率与死亡率的关系。
Circ Res. 2020 Jun 5;126(12):1671-1681. doi: 10.1161/CIRCRESAHA.120.317134. Epub 2020 Apr 17.
7
Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19.高血压、肾素-血管紧张素系统与下呼吸道感染和肺损伤风险：对 COVID-19 的影响。
Cardiovasc Res. 2020 Aug 1;116(10):1688-1699. doi: 10.1093/cvr/cvaa097.
8
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
9
Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?在新冠疫情期间，血管紧张素受体阻断药物是否可能有害？
J Hypertens. 2020 May;38(5):781-782. doi: 10.1097/HJH.0000000000002450.
10
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.血管紧张素转换酶2是严重急性呼吸综合征冠状病毒的功能性受体。
Nature. 2003 Nov 27;426(6965):450-4. doi: 10.1038/nature02145.
Zotero 插件